<DOC>
	<DOCNO>NCT01919164</DOCNO>
	<brief_summary>This multicenter , randomize , double-blind , placebo-controlled , parallel-group Phase 2 trial AS902330 administer intra-articularly subject primary osteoarthritis knee Kellgren-Lawrence Grade 2 3 . The trial intend investigate efficacy safety different intra articular dosage AS902330 ( Sprifermin ) individual .</brief_summary>
	<brief_title>A Study Investigate Safety Effectiveness Different Doses Sprifermin ( AS902330 ) Patients With Osteoarthritis Knee</brief_title>
	<detailed_description>Subjects equally randomize either one 4 treatment arm placebo arm . The trial consist Screening period last 42 day , two-year double-blind placebo-controlled ( DBPC ) treatment phase , begin randomization ( Week 0 ) end Year 2 , 3-year extend follow-up phase .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Age 40 85 year ; either sex Primary femorotibial osteoarthritis accord American College Rheumatology ( ACR ) clinical radiographic criterion , meet protocolspecified Xray criterion target knee screen Pain score target knee and/or need regular symptomatic treatment knee pain paracetamol ( acetaminophen ) , systemic nonsteroidal antiinflammatory drug ( NSAIDs ) include cyclooxygenase ( COX ) 2 selective inhibitor ( coxibs ) , tramadol day previous month ( , half day previous month ) A history pain due Osteoarthritis target knee least 6 month A protocolspecified pain score target knee response Question 1 WOMAC pain index ( `` much pain [ target knee , past 48 hour ] walk flat surface ? '' ) washout least 5 halflives analgesic medication ( ) : acetaminophen , topical oral NSAIDS , coxibs , opioids , and/or tramadol Women childbearing potential must use form contraception failure rate le 1 percent per year throughout trial Malalignment great 5 degree femorotibial axis target knee Clinical sign inflammation ( redness ) target knee Intraarticular administration corticosteroid hyaluronic acid either knee within 6 month Screening Planned knee surgery ( affect either target contralateral knee ) within next two year Concomitant condition treatment deem incompatible trial participation Any contraindication MRI accord MRI guideline , include inability undergo knee MRI exam inability fit scanner knee coil Pregnancy breastfeed Participation another clinical trial within 30 day ( 5 halflives investigate compound , whichever long ) screen Legal incapacity limit legal capacity</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Osteoarthritis knee</keyword>
	<keyword>AS902330</keyword>
	<keyword>Recombinant Human Fibroblast Growth Factor-18 ( rhFGF-18 )</keyword>
	<keyword>Sprifermin</keyword>
	<keyword>Placebo</keyword>
</DOC>